OSAKA, Japan, March 19, 2026
Shionogi & Co., Ltd. has officially announced the commercial launch of ZURZUVAE® (zuranolone) 30 mg capsules for the treatment of major depressive disorder (MDD) in Japan, marking a significant advancement in rapid-acting antidepressant therapy. The drug introduces a novel mechanism targeting GABA_A receptors, offering faster symptom relief compared to traditional antidepressants.
Rapid-Acting Antidepressant with Novel Mechanism
ZURZUVAE represents a next-generation oral antidepressant designed to address limitations of existing therapies. Unlike conventional treatments that often take weeks to show effect, ZURZUVAE acts as a positive allosteric modulator of GABA_A receptors, functioning at both synaptic and extrasynaptic sites to deliver rapid improvement in depressive symptoms. This innovative mechanism positions the therapy as a potential paradigm shift in depression treatment, especially for patients requiring urgent symptom control.
Depression remains a major public health burden in Japan, affecting approximately 5 million people, with many patients experiencing delayed relief due to the slow onset of standard medications. The introduction of ZURZUVAE aims to fill this critical unmet medical need by enabling faster therapeutic response and improving patient outcomes.
Strong Phase 3 Clinical Evidence Supports Approval
Advertisement
The approval and launch of ZURZUVAE are supported by robust Phase 3 randomized, placebo-controlled clinical trial data conducted in Japan. In the study, adult patients receiving 30 mg once daily for 14 consecutive days demonstrated rapid and significant improvement in depressive symptoms, highlighting the drug’s clinical effectiveness. Importantly, no major safety concerns were identified, even upon re-administration, reinforcing confidence in its safety profile.
This strong clinical evidence underscores the drug’s potential to transform treatment timelines in MDD, offering both efficacy and safety within a short dosing regimen. The therapy’s design also allows for repeat treatment cycles with appropriate intervals, making it adaptable to patient needs in real-world settings.
Regulatory Milestone and Market Launch
ZURZUVAE received marketing approval on December 22, 2025, followed by NHI price listing on March 18, 2026, and was officially launched on March 19, 2026 in Japan. This rapid progression from approval to commercialization reflects strong regulatory confidence and readiness for market adoption.
The drug is administered as a once-daily oral capsule for 14 days, offering a convenient and patient-friendly dosing regimen. Its launch strengthens Shionogi’s commitment to delivering innovative healthcare solutions addressing high-impact quality-of-life diseases, including mental health conditions that significantly affect societal and economic well-being.
Advancing Mental Health Treatment Landscape
With its rapid onset of action, novel pharmacological approach, and strong clinical backing, ZURZUVAE is expected to play a key role in reshaping the depression treatment landscape. The therapy not only addresses long-standing gaps in treatment speed but also aligns with the broader goal of improving patient quality of life through timely and effective intervention.
Shionogi’s strategic focus on research, development, and commercialization of innovative therapies further highlights the importance of integrating clinical excellence with regulatory compliance, reinforcing the role of GxP principles in bringing advanced treatments to market.
Source: Shionogi press release
